the aid library

LIST OPTIONS

Filter

1862

Sort by:

Direction:

Download (192)

View PDF (114)

Financing for Sustainable Development Report 2022

Inter-agency Task Force on Financing for Development United Nations (UN) (2022) CC

The 2022 Financing for Sustainable Development Report identifies a “great finance divide” as a main driver of the divergent recovery. Developed countries were able to borrow record sums at ultra-low interest rates to support their people and economies, but the pandemic response and investment in... more

Download (128)

View PDF (129)

Working Paper 46 - Aid, China, and Growth: Evidence from a New Global Development Finance Dataset

Dreher, A.; A. Fuchs; B. Parks et al. AidData at William & Mary (2017) CC

This paper introduces a new dataset of official financing—including foreign aid and other forms of concessional and non-concessional state financing—from China to 138 countries between 2000 and 2014. We use these data to investigate whether and to what extent Chinese aid affects economic growth ... more

Download (93)

View PDF (108)

Estimating Financing to the Sustainable Development Goals: Methodology Note for V2.0.

Turner, Jennifer, and Bryan Burgess AidData at William & Mary (2019) CC

Unfortunately, current data available on SDG financing are not sufficient to quantify the distribution of financing for the SDGs. AidData’s methodology for measuring financing to the SDGs attempts to fill this gap by analyzing development project documentation to estimate project-level contributi... more

Download (110)

View PDF (107)

Realizing Agenda 2030: Will donor dollars and country priorities align with global goals?

Sethi, T.; S. Custer; J. Turner et al. AidData at William & Mary (2017) CC

This report seeks to uncover the extent to which global goals crowd in international financing, inform domestic policy priorities, and navigate progress toward development outcomes in low- and middle-income countries (LICs and MICs). Our report: Provides a historical perspective on how ODA financin... more

Download (105)

View PDF (485)

Chinese development assistance and household welfare in sub-Saharan Africa

Bruno Martorano, Laura Metzger, Marco Sanfilippo European University Institute (2019) C1

We combine data on Chinese development projects with data from Demographic and Health Surveys to study the impact of Chinese aid on household welfare in sub-Saharan Africa. We use a novel methodology to test the effect of Chinese aid on three important development outcomes: education, health, and nu... more

Download (118)

View PDF (429)

Donor Funding for Newborn Survival: An Analysis of Donor-Reported Data, 2002–2010

Pitt1, C.; J. E. Lawn; M. Ranganathan et al. PLoS Med (2012) CC

Background:Neonatal mortality accounts for 43% of global under-five deaths and is decreasing more slowly than maternal or child mortality. Donor funding has increased for maternal, newborn, and child health (MNCH), but no analysis to date has disaggregated aid for newborns. We evaluated if and how a... more

Download (116)

View PDF (164)

Financing for Sustainable Development Report 2020

Inter-agency Task Force on Financing for Development United Nations (UN) (2020) CC

The 2020 Financing for Sustainable Development Report, the fifth report of the Inter-agency Task Force on Financing for Development, provides a comprehensive assessment of the state of sustainable finance. Prepared by more than 60 agencies of the United Nations system and partner international organ... more

Download (162)

View PDF (215)

WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

World Health Organization WHO (2021) C_WHO

The global burden of disease associated with air pollution exposure exacts a massive toll on human health worldwide: exposure to air pollution is estimated to cause millions of deaths and lost years of healthy life annually. The burden of disease attributable to air pollution is now estimated to be ... more

Download (169)

View PDF (139)

Compendium of WHO and other UN guidance on health and environment: version with International Classification of Health Intervention (‎ICHI)‎ codes

World Health Organization WHO (2024) C_WHO

In this version of the compendium, each guidance is coded using the International Classification of Health Interventions (ICHI). The compendium provides a systematic compilation of published guidance from WHO and other UN organizations on health and environment. Guidance on policies and actions a... more

Download (134)

View PDF (122)

Laboratory manual for yellow fever
recommended

World Health Organization WHO (2024) C_WHO

This WHO laboratory manual provides the most up to date methods and procedures for the laboratory identification of yellow fever virus infection in humans. It provides guidance on the establishment and maintenance of an effective laboratory providing routine surveillance testing for yellow fever, wh... more

Download (227)

View PDF (116)

Analysis of Pandemic Preparedness and Response (PPR) architecture, financing needs, gaps and mechanisms

World Bank (2022) CC

A global Pandemic, Preparedness and Response (RRR) architecture

Download (157)

View PDF (163)

A guide to implementing the One Health Joint Plan of Action at national level
recommended

World Health Organization WHO; Food and Agriculture Organization of the United Nations FAO; UN UN Environment Programme UNEP; World Organisation for Animal Health WOAH (2023) C_WHO

The guide to implementing the One Health Joint Plan of Action (OH JPA) at national level provides practical guidance on how countries can adopt and adapt the OH JPA to strengthen and support national One Health action. Building on the OH JPA theory of change, this guide describes three pathways a... more

Download (232)

View PDF (415)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (273)

View PDF (368)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (130)

View PDF (349)

Climate Risk Sourcebook

Deutsche Gesellschaft für Internationale Zusammenarbeit GIZ; Eurac Research; United Nations University (2023) CC

Climate change is one of the most urgent challenges for people and ecosystems worldwide. The recently published sixth Assessment Report (AR6) of the Intergovernmental Panel on Climate Change (IPCC) stresses the occurrence of widespread adverse impacts of climate change. Increased frequency and inten... more

Download (1972)

View PDF (3183)

Environmental Health In Emergencies And Disasters: A Practical Guide
recommended

Wisner, B; Adams, J Word Health Organization WHO (2022) C_WHO

The present book deals not only with emergency response, but also with measures designed to reduce the impact of disasters on environmental health infrastructure, such as water supply and sanitation facilities. It also aims to strengthen the ability of people to withstand the disruption of their acc... more

Download (315)

View PDF (2794)

Guide for Emergency Preparedness and Correct Action in Emergency Situations
recommended

Federal Office of Civil Protection and Disaster Assistance (BBK) (2017) C3

Staying safe in spite of a disaster. What can you do for your safety in the event of a disaster? In spring 2013, after weeks of rain, whole areas of southern, eastern and northern Germany were beset by catastrophic floods. Settlements vanished in th... more

Download (132)

View PDF (153)

Tracking Japan’s development assistance for health, 2012–2016

Nomura, S.; H. Sakamoto; M. K. Sugai et al. Globalization and Health (2020) CC

: Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarified its... more

Download (215)

View PDF (211)

Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans

Quadripartite: Food and Agriculture Organization of the United Nations FAO; UN Environment Programme UNEP; World Health Organization WHO; World Organisation for Animal Health WAHO (2023) CC

Antimicrobial resistance (AMR) is a global human, animal, plant and environment health threat that needs to be addressed by every country. The impacts of AMR are wide-ranging in terms of human health, animal health, food security and safety, environmental effects on ecosystems and biodiversity, and ...socioeconomic development. Just like the climate crisis, AMR poses a significant threat to the delivery of the 2030 Agenda for Sustainable Development. The response to the AMR crisis has been spearheaded through the global action plan on antimicrobial resistance (GAP-AMR), developed by the World Health Organization (WHO) in 2015, in close collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), and formally endorsed by the three organizations’ governing bodies and by the Political Declaration of the high-level meeting of the United Nations General Assembly on AMR in 2016. In 2022, the three organizations officially became the Quadripartite by welcoming the United Nations Environment Programme (UNEP) into the alliance “to accelerate coordination strategy on human, animal and ecosystem health”. The aim of the GAP-AMR is to ensure the continuity of successful treatment with effective and safe medicines. Its strategic objectives include: • improving the awareness and understanding of AMR; • strengthening the knowledge and evidence base through surveillance and research; • reducing the incidence of infection through effective sanitation, hygiene and infection prevention measures; optimizing the use of antimicrobial medicines in human and animal health; and • developing the economic case for sustainable investment that takes account of the needs of all countries and increasing investment in new medicines, diagnostic tools, vaccines and other interventions. With the adoption of the GAP-AMR, countries agreed to develop national action plans (NAPs) aligned with the GAP-AMR to mainstream AMR interventions nationally. Individually, the Quadripartite took action to advance AMR interventions in their respective sectors. FAO adopted a resolution on AMR recognizing that it poses an increasingly serious threat to public health and sustainable food production, and developed an AMR action plan to support the resolution’s implementation. For its part, WOAH developed a strategy on AMR aligned with the GAP-AMR, acknowledging the importance of a One Health approach to AMR. Similarly, more recently, UNEP’s governing body, the United Nations Environment Assembly, recognized that AMR is a current and increasing threat and a challenge to global health, food security and the sustainable development of all countries, and welcomed the GAP-AMR and the NAPs developed in accordance with its five overarching strategic objectives more

Download (159)

View PDF (593)

Manejo clínico de la fiebre amarilla en la Región de las Américas. Experiencias y recomendaciones para los servicios de salud

Pan American Health Organization PAHO (2023) CC

Las olas de transmisión de la fiebre amarilla ocurridas en la Región de las Américas entre el 2016 y el 2018 causaron el mayor número de casos humanos y epizoóticos registrados en varios decenios. La fiebre amarilla es una enfermedad hemorrágica viral grave que representa un desafío para el p... more

Laboratory manual for yellow fever recommended

A guide to implementing the One Health Joint Plan of Action at national level recommended

Environmental Health In Emergencies And Disasters: A Practical Guide recommended

Guide for Emergency Preparedness and Correct Action in Emergency Situations recommended

Laboratory manual for yellow fever
recommended

A guide to implementing the One Health Joint Plan of Action at national level
recommended

Environmental Health In Emergencies And Disasters: A Practical Guide
recommended

Guide for Emergency Preparedness and Correct Action in Emergency Situations
recommended